Informations générales (source: ClinicalTrials.gov)
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
Observational
Seagen, a wholly owned subsidiary of Pfizer (Voir sur ClinicalTrials)
juin 2023
juillet 2025
17 avril 2025
This study is being done to learn about urothelial cancers that make HER2 and how that
affects treatment choices for participants with urothelial cancer. During this study, the
medical and health records of participants will be reviewed to learn more about their
health.
Participants will have urothelial cancer that has grown in the body near where it started
(locally advanced) and cannot be removed (unresectable) or has spread through the body
(metastatic).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - 69373 - Lyon - France | Contact (sur clinicalTrials) | ||||
| CHU de Rouen. - 76000 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Institut Mutualiste Montsouris - 75674 - Paris - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or
urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is
the predominant cell type.
- Locally advanced unresectable or metastatic stage disease
- Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned
slides, see laboratory manual for details) available for HER2 testing.
- At least 1 prior line of systemic therapy for locally advanced unresectable or
metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing
chemotherapy.
- Initiation of anticancer therapy for UC after prior progression on platinum-based
therapy with or without maintenance avelumab between 01 January 2019 and 12 months
before the end of data collection
- Radiographically documented and measurable disease progression immediately before
index date
- Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or
urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is
the predominant cell type.
- Locally advanced unresectable or metastatic stage disease
- Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned
slides, see laboratory manual for details) available for HER2 testing.
- At least 1 prior line of systemic therapy for locally advanced unresectable or
metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing
chemotherapy.
- Initiation of anticancer therapy for UC after prior progression on platinum-based
therapy with or without maintenance avelumab between 01 January 2019 and 12 months
before the end of data collection
- Radiographically documented and measurable disease progression immediately before
index date
- Any concurrent malignant neoplasm requiring systemic therapy during the study window
- Enrollment in a therapeutic clinical trial and received non-standard of care
treatment during index line of therapy